Maine News Reporter

The Sleep Apnea Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Sleep Apnea Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sleep Apnea Market.

Some of the key takeaways from the Sleep Apnea Pipeline Report:

• Companies across the globe are diligently working toward developing novel Sleep Apnea treatment therapies with a considerable amount of success over the years.

• Sleep Apnea companies working in the treatment market are Apnimed, Eli Lilly and Company, Incannex Healthcare, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet, and others, are developing therapies for the Sleep Apnea treatment

• Emerging Sleep Apnea therapies in the different phases of clinical trials are- AD109 (Aroxybutynin + Atomoxetine), Retatrutide, Orforglipron, IHL-42X (Acetazolamide + dronabinol), ZEPBOUND/ MOUNJARO (tirzepatide), SUNOSI (solriamfetol), OZAWADE (Pitolisant), and others are expected to have a significant impact on the Sleep Apnea market in the coming years.

• In June 2026, Eli Lilly reported encouraging results from late-stage clinical trials evaluating retatrutide in adults with obesity and obstructive sleep apnea (OSA). The investigational triple GIP/GLP-1/glucagon receptor agonist demonstrated significant reductions in OSA severity while producing substantial weight loss, highlighting the potential of metabolic therapies as an effective treatment approach for sleep apnea.

• In May 2026, Apnimed announced positive topline results from its Phase III SynAIRgy trial evaluating AD109, an investigational once-nightly oral therapy for obstructive sleep apnea (OSA). The trial showed significant reductions in the apnea-hypopnea index (AHI) and meaningful improvements in disease severity, supporting the company’s plans to pursue regulatory submissions.

• In March 2026, LivaNova’s aura6000™ hypoglossal nerve stimulation system received FDA Premarket Approval (PMA) for the treatment of adults with moderate-to-severe obstructive sleep apnea (OSA) who are unable to tolerate or have not responded adequately to positive airway pressure (PAP) therapy. The implantable neurostimulation device provides an alternative therapeutic option for eligible patients with OSA.

• In July 2025, Apnimed reported positive topline findings from LunAIRo, its second Phase 3 trial of AD109 (aroxybutynin 2.5 mg, atomoxetine 75 mg) in adults with obstructive sleep apnea. Earlier, in May, the company shared results from its SynAIRgy trial of AD109.T

• In May 2025, LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, today released 12-month top-line results from its OSPREY randomized controlled trial (RCT), assessing the efficacy of the aura6000™ System for treating moderate to severe obstructive sleep apnea (OSA). After 12 months of treatment, the responder rate in the therapy group was 65%, with responders defined as patients achieving at least a 50% reduction from baseline in the apnea-hypopnea index (AHI) and an AHI below 20. The study highlights a unique neurostimulation approach called proximal hypoglossal nerve stimulation (p-HGNS), which uses six electrodes placed on the proximal trunk of the hypoglossal nerve to broadly target airway muscles and allow personalized therapy adjustments.

• In May 2025, Apnimed reported positive Phase III SynAIRgy trial results for AD109, an oral OSA therapy. The study achieved its primary endpoint, demonstrating a significant reduction in the apnea-hypopnea index (AHI) at 26 weeks compared to placebo. Effectiveness was observed across all severities of OSA and various weight groups. AD109 was well-tolerated, with no serious treatment-related adverse events. These findings support AD109’s potential as a first-in-class oral treatment for OSA.

• In Jan 2025, Mineralys Therapeutics, Inc. announced that the FDA has approved its IND application for a Phase 2 clinical trial to assess lorundrostat for the treatment of Sleep Apnea (OSA) and hypertension. The trial is set to begin in the first quarter of 2025.

• In January 2025, Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company dedicated to developing treatments for hypertension, chronic kidney disease (CKD), and other conditions related to aldosterone imbalance, announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application. This approval allows the company to begin a Phase 2 clinical trial assessing the effects of lorundrostat in patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension. The trial is expected to commence in the first quarter of 2025.

Sleep Apnea Overview

Sleep apnea is a common sleep disorder where breathing repeatedly stops and starts during sleep. It can cause loud snoring, gasping for air, and excessive daytime sleepiness. The two main types are obstructive sleep apnea (caused by blocked airways) and central sleep apnea (caused by brain signaling issues). If left untreated, it can lead to serious health problems like high blood pressure, heart disease, and stroke.

Get a Free Sample PDF Report to know more about Sleep Apnea Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/sleep-apnea-pipeline-insight

Emerging Sleep Apnea Drugs Under Different Phases of Clinical Development Include:

• AD109 (Aroxybutynin + Atomoxetine): Apnimed

• Retatrutide: Eli Lilly and Company

• Orforglipron: Eli Lilly and Company

• IHL-42X (Acetazolamide + dronabinol): Incannex Healthcare

• ZEPBOUND/ MOUNJARO (tirzepatide): Eli Lilly and Company

• SUNOSI (solriamfetol): Axsome Therapeutics/Jazz Pharmaceuticals

• OZAWADE (Pitolisant): Bioprojet

Sleep Apnea Pipeline Therapeutics Assessment

• Sleep Apnea Assessment by Product Type

• Sleep Apnea By Stage and Product Type

• Sleep Apnea Assessment by Route of Administration

• Sleep Apnea By Stage and Route of Administration

• Sleep Apnea Assessment by Molecule Type

• Sleep Apnea by Stage and Molecule Type

DelveInsight’s Sleep Apnea Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Sleep Apnea product details are provided in the report. Download the Sleep Apnea pipeline report to learn more about the emerging Sleep Apnea therapies

Some of the key companies in the Sleep Apnea Therapeutics Market include:

Key companies developing therapies for Sleep Apnea are – Apnimed, Eli Lilly and Company, Therapix Biosciences, Bioprojet Pharma, Axsome Therapeutics/ Jazz Pharmaceuticals and others.

Sleep Apnea Pipeline Analysis:

The Sleep Apnea pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Sleep Apnea with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sleep Apnea Treatment.

• Sleep Apnea key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sleep Apnea market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sleep Apnea drugs and therapies

Sleep Apnea Pipeline Market Drivers

• Increase in prevalence of Sleep Apnea (OSA), rising awareness of the disorder are some of the important factors that are fueling the Sleep Apnea Market.

Sleep Apnea Pipeline Market Barriers

• However, lack of Approved Drugs, complexity of OSA pathogenesis and other factors are creating obstacles in the Sleep Apnea Market growth.

Scope of Sleep Apnea Pipeline Drug Insight

• Coverage: Global

• Key Sleep Apnea Companies: Apnimed, Eli Lilly and Company, Incannex Healthcare, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet, and others

• Key Sleep Apnea Therapies: AD109 (Aroxybutynin + Atomoxetine), Retatrutide, Orforglipron, IHL-42X (Acetazolamide + dronabinol), ZEPBOUND/ MOUNJARO (tirzepatide), SUNOSI (solriamfetol), OZAWADE (Pitolisant), and others

• Sleep Apnea Therapeutic Assessment: Sleep Apnea current marketed and Sleep Apnea emerging therapies

• Sleep Apnea Market Dynamics: Sleep Apnea market drivers and Sleep Apnea market barriers

Request for Sample PDF Report for Sleep Apnea Pipeline Assessment and clinical trials

Table of Contents

1. Sleep Apnea Report Introduction

2. Sleep Apnea Executive Summary

3. Sleep Apnea Overview

4. Sleep Apnea- Analytical Perspective In-depth Commercial Assessment

5. Sleep Apnea Pipeline Therapeutics

6. Sleep Apnea Late Stage Products (Phase II/III)

7. Sleep Apnea Mid Stage Products (Phase II)

8. Sleep Apnea Early Stage Products (Phase I)

9. Sleep Apnea Preclinical Stage Products

10. Sleep Apnea Therapeutics Assessment

11. Sleep Apnea Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sleep Apnea Key Companies

14. Sleep Apnea Key Products

15. Sleep Apnea Unmet Needs

16 . Sleep Apnea Market Drivers and Barriers

17. Sleep Apnea Future Perspectives and Conclusion

18. Sleep Apnea Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/